Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | KIT amp |
| Gene Variant Detail | |
| Relevant Treatment Approaches | KIT Inhibitor |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| KIT amp | melanoma | no benefit | KIT Inhibitor | Imatinib | Phase II | Actionable | In a Phase II trial, Gleevec (imatinib) treatment resulted in limited efficacy in patients with mucosal, acral, or chronically sun-damaged skin melanoma harboring KIT amplification, with a best overall response rate of 0% (0/11), a disease control rate of 18.2% (2/11), a time to progression of 3.4 months, and a median overall survival of 11.9 months (PMID: 23775962; NCT00424515). | 23775962 |